Lučenec

Slovakia

35 total trials 7 recruiting

Filter these 35 trials by phase, condition, sponsor and more.

Open in Search →

A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended

2023-503785-22-00 5 2024-03-25 complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo … Ended

2023-506197-12-00 4 2024-02-07 Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended

2023-503790-37-00 5 2024-01-09 Post-Menopausal Osteoporosis
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 5 2023-09-05 Obesity
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase … Ended

2022-502833-25-00 5 2023-08-02 Obesity
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended

2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine … Ended

2024-510612-75-00 5 2022-08-31 Participants with T2D and overweight
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended

2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok

Showing 25–35 of 35 trials